{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hormone+Receptor-Positive+Breast+Carcinoma&page=2", "query": { "condition": "Hormone Receptor-Positive Breast Carcinoma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hormone+Receptor-Positive+Breast+Carcinoma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-10T15:17:42.178Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06974604", "title": "Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Neoplasms", "Lung Neoplasms" ], "interventions": [ { "name": "Dexamethasone oral", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2025-10-22", "completion_date": "2029-05-31", "has_results": false, "last_update_posted_date": "2025-10-24", "last_synced_at": "2026-06-10T15:17:42.178Z", "location_count": 1, "location_summary": "Providence, Rhode Island", "locations": [ { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT06974604" }, { "nct_id": "NCT02118636", "title": "Observational Study to Evaluate Mechanisms of Aromatase Inhibitor Associated Musculoskeletal Symptoms", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer", "Arthralgia" ], "interventions": [], "intervention_types": [], "sponsor": "Lynn Henry", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "FEMALE", "summary": "21 Years and older · Female only" }, "enrollment_count": 75, "start_date": "2009-10", "completion_date": "2015-09", "has_results": false, "last_update_posted_date": "2016-03-07", "last_synced_at": "2026-06-10T15:17:42.178Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02118636" }, { "nct_id": "NCT03691493", "title": "Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Estrogen Receptor Positive", "HER2/Neu Negative", "Metastatic Breast Carcinoma", "Metastatic Malignant Neoplasm in the Bone", "Progesterone Receptor Positive", "Prognostic Stage IV Breast Cancer AJCC v8" ], "interventions": [ { "name": "Anastrozole", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Tamoxifen", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2019-02-08", "completion_date": "2022-10-13", "has_results": true, "last_update_posted_date": "2025-02-17", "last_synced_at": "2026-06-10T15:17:42.178Z", "location_count": 10, "location_summary": "Atlanta, Georgia • Augusta, Georgia • Columbus, Georgia + 2 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03691493" }, { "nct_id": "NCT01698918", "title": "Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hormone Receptor Positive Breast Cancer" ], "interventions": [ { "name": "Everolimus", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Alcohol-free dexamethasone mouth rinse (Stomatitis sub-study)", "type": "DRUG" }, { "name": "Standard of care to treat stomatitis (Stomatitis sub-study)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 202, "start_date": "2013-03-07", "completion_date": "2021-01-13", "has_results": true, "last_update_posted_date": "2023-05-03", "last_synced_at": "2026-06-10T15:17:42.178Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Loma Linda, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Loma Linda", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Park Ridge", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01698918" }, { "nct_id": "NCT05735080", "title": "Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Breast Cancer Metastatic", "Hormone Receptor Positive Tumor", "Human Epidermal Growth Factor 2 Negative Carcinoma of Breast", "Ovarian Cancer", "CCNE1 Amplification", "Solid Tumor", "Advanced Cancer", "Metastatic Cancer" ], "interventions": [ { "name": "INX-315", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyclix Bio", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2023-03-28", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-06-10T15:17:42.178Z", "location_count": 15, "location_summary": "Orlando, Florida • Atlanta, Georgia • Augusta, Georgia + 10 more", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05735080" }, { "nct_id": "NCT03088527", "title": "Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hormone Receptor Positive Malignant Neoplasm of Breast" ], "interventions": [ { "name": "RAD140", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stemline Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 20, "start_date": "2017-10-23", "completion_date": "2020-09-24", "has_results": false, "last_update_posted_date": "2022-08-18", "last_synced_at": "2026-06-10T15:17:42.178Z", "location_count": 5, "location_summary": "New Haven, Connecticut • Boston, Massachusetts • Detroit, Michigan + 2 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03088527" }, { "nct_id": "NCT05447910", "title": "Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative Breast Cancer", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Adenocarcinoma", "Invasive Breast Carcinoma", "Resectable Breast Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 21, "start_date": "2022-07-21", "completion_date": "2023-09-27", "has_results": false, "last_update_posted_date": "2025-06-15", "last_synced_at": "2026-06-10T15:17:42.178Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05447910" }, { "nct_id": "NCT06361940", "title": "Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Aromatase inhibitors or tamoxifen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 100, "start_date": "2024-09-30", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2025-10-14", "last_synced_at": "2026-06-10T15:17:42.178Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT06361940" }, { "nct_id": "NCT02115282", "title": "Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Breast Adenocarcinoma", "HER2/Neu Negative", "Locally Advanced Breast Carcinoma", "Metastatic Breast Carcinoma", "Recurrent Breast Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Entinostat", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Goserelin", "type": "DRUG" }, { "name": "Goserelin Acetate", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Placebo Administration", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 608, "start_date": "2014-03-29", "completion_date": "2026-06-02", "has_results": true, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-06-10T15:17:42.178Z", "location_count": 654, "location_summary": "Birmingham, Alabama • Jonesboro, Arkansas • Carmichael, California + 461 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Carmichael", "state": "California" }, { "city": "Chico", "state": "California" }, { "city": "Chico", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02115282" }, { "nct_id": "NCT03394027", "title": "ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Triple Negative Breast Cancer", "Endometrial Cancer", "Hormone Receptor Positive, HER2 Negative Breast Cancer" ], "interventions": [ { "name": "ONC201", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2018-01-17", "completion_date": "2021-10-07", "has_results": true, "last_update_posted_date": "2022-08-23", "last_synced_at": "2026-06-10T15:17:42.178Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03394027" } ] }